Current systemic treatment strategies for hidradenitis suppurativa

References

• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venerolog. 2015;29:619–644.
   Google Scholar
• Bettoli V, Join-Lambert O, Nassif A. Antibiotic treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34:81–89.
   Google Scholar
• Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016 Feb 1;17:343–351.
   Google Scholar
• Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S42–6.
   Google Scholar
• Nikolakis G, Join-Lambert O, Karagiannidis I, et al. Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S12–8.
   Google Scholar
• Matusiak Ł, Bieniek A, Szepietowski JC. Bacteriology of hidradenitis suppurativa – which antibiotics are the treatment of choice? Acta Derm Venerol. 2014;94:699–702.
   Google Scholar
• Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2017 Feb;76(2):309–313.
   Google Scholar
• Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;38:971.
   Google Scholar
• Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219:148.
   Google Scholar
• Mendoca CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatology. 2006;154:977–978.
   Google Scholar
• Van Der Zee HH, Boer J, Prens EP, et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143–147.
   Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al., Society for Healthcare Epidemiology of America.; Infectious Diseases Society of America. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–455.
   Google Scholar
• Bauer MP, Kuijper EJ, Van Dissel JT, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067–1079.
   Google Scholar
• Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011;222:49–58.
   Google Scholar
• Join-Lambert O, Coignard-Biehler H, Jais JP, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016;71:513–520.
   Google Scholar
• Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222:342–346.
   Google Scholar
• Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. 2006;17:211–213.
   Google Scholar
• Jemec GBE, Revuz J. Treatment. In: Jemec GBE, Revuz J, Leyden JL, eds. Hidradenitis Suppurativa. Germany: Springer; 2006. p. 183–186.
   Google Scholar
• Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23:985–998.
   Google Scholar
• Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol. 1988;19:355–356.
   Google Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment of hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171:170–174.
   Google Scholar
• Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170–175.
   Google Scholar
• Verdolini R, Simonacci F, Menon S, et al. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in woman of child-bearing age. G Ital Dermatol Venereol. 2015 Apr;150(2):155–162.
   Google Scholar
• Boer J, Van Gemert MJ. Long-term results of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73.
   Google Scholar
• Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology. 2009;218:134.
   Google Scholar
• Mortimer PS, Dawbar RP, Gales MA, et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263–268.
   Google Scholar
• Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg. 2007 Jul-Aug;11(4):125–131.
   Google Scholar
• Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in woman using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115:269–274.
   Google Scholar
• Farrell AM, Randall VA, Vafaee T, et al. Finasteride as a therapy for hidradenitis suppurativa. Br J Dermatol. 1999;141:1138–1139.
   Google Scholar
• Joseph MA, Jayaseelan E, Ganapathi B, et al. Hidradenitis suppurativa treated with finasteride. Jour of Dermatol Treatment. 2005;16:75–78.
   Google Scholar
• Randhawa HK, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol. 2013;149:732–735.
   Google Scholar
• Samplaski MK, Lo K, Grober E, et al. Finasteride use in male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100:1542–1546.
   Google Scholar
• Brocard A, Knol AC, Khammari A, et al. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology. 2007;214:325–327.
   Google Scholar
• Hessam S, Sand M, Meier NM, et al. Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa. J Dermatol Sci. 2016 Aug 10;84:197–202.
   Google Scholar
• Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol. 1996;135:721–725.
   Google Scholar
• Anderson MD, Zauli S, Bettoli V, et al. Cyclosporine treatment of severe hidradenitis suppurativa - a case series. J Dermatolog Treat. 2016;27:247–250.
   Google Scholar
• Van Der Zee HH, Wayne GP. Medical treatments of hidradenitis suppurativa: more options, less evidence. Dermatol Clin. 2016;34:91–96.
   Google Scholar
• Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic agents. J Am Acad Dermatol. 2015;73:S82–3.
   Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   Google Scholar
• Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br. J. Dermatol. 2011;165:391–398.
   Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;18;157:846–855.
   Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016 4;375:422–434.
   Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–217.
   Google Scholar
• Paradela S, Rodriguez-Lojo R, Fernandez-Torres R, et al. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat. 2012;23:278–283.
   Google Scholar
• vanRappard DC, Leenarts MF, Van Meijerink-Van ‘T Oost L, et al. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2012;23;23:284–289.
   Google Scholar
• Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–504.
   Google Scholar
• Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726–729.
   Google Scholar
• Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567–572.
   Google Scholar
• Dinarello CA. van der Meer JW. Treating inflammation by targeting IL-1 in humans. Semin Immunol. 2013;15;25:469–484.
   Google Scholar
• Leslie KS, Tripathi SV, Nguyen TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70:243–251.
   Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and Efficiency of Anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2015;172:820.
   Google Scholar
• Menis D, Maroñas-Jiménez L, Delgado-Marquez AM, et al. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol. 2015;172:810–811.
   Google Scholar
• Russo V, Alikhan A. Failure of anakinra in a case of severe hidradenitis suppurativa: a case report. J Drugs Dermatol. 2016;1;15:772–774.
   Google Scholar
• Van Der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226:97–100.
   Google Scholar
• Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839–846.
   Google Scholar
• Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26:911–914.
   Google Scholar
• Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92:320–321.
   Google Scholar
• Baerveldt EM, Kappen JH, Thio HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behcet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72:626–627.
   Google Scholar
• Santos-Perez MI. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr. 2014;105:720–722.
   Google Scholar
• Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol. 2015;73(5 Suppl 1):S82–8.
   Google Scholar
• Revuz J. Ann Dermatol Venereol. 2012;139:532–541.
   Google Scholar